ArticleLeukemia & lymphoma2010
Osteolytic bone resorption in adult T-cell leukemia/lymphoma.
Article in Leukemia & lymphoma, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Giant cell tumor of bone inhibits osteoblastogenesis via WNT5B.Journal of bone and mineral metabolism · 2026Article
- HTLV-1 infected T cells cause bone loss via small extracellular vesicles.Journal of extracellular vesicles · 2024Article
- Article
- In Vivo Tumorigenesis, Osteolytic Sarcomas, and Tumorigenic Cell Lines from Transgenic Mice Expressing the Human T-Lymphotropic Virus Type 1 (HTLV-1) Tax Viral Oncogene.The American journal of pathology · 2021Article
- Parathyroid hormone-related protein promotes bone loss in T-cell leukemia as well as in solid tumors.Leukemia & lymphoma · 2020Article
- Mouse model recapitulates the phenotypic heterogeneity of human adult T-cell leukemia/lymphoma in bone.Journal of bone oncology · 2019Article
- Article
- Article
- Evaluation of the role ofBlood research · 2017Article
- Animal Models of Cancer-Associated Hypercalcemia.Veterinary sciences · 2017Review
- Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.Endocrine reviews · 2016Review
- The thyroid status reprograms T cell lymphoma growth and modulates immune cell frequencies.Journal of molecular medicine (Berlin, Germany) · 2016Article
- Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.Veterinary and comparative oncology · 2015Article
- An unusual case of malignancy-related hypercalcemia.International journal of general medicine · 2013Article
- Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma.Oral oncology · 2012Article
- Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences.Journal of bone oncology · 2012Review
- Effects of parathyroid hormone-related protein and macrophage inflammatory protein-1α in Jurkat T-cells on tumor formation in vivo and expression of apoptosis regulatory genes in vitro.Leukemia & lymphoma · 2012Article
- Retrovirus-transformed erythroleukemia cells induce central nervous system failure in a new syngeneic mouse model of meningeal leukemia.Leukemia research · 2012Article
- Pathogenesis of Metastatic Calcification and Acute Pancreatitis in Adult T-Cell Leukemia under Hypercalcemic State.Leukemia research and treatment · 2012Article
- Hematopoietic cell regulation of osteoblast proliferation and differentiation.Current osteoporosis reports · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Adult T-cell leukemia/lymphoma (ATLL) is caused by human T lymphotropic virus type 1 (HTLV-1). Patients with ATLL frequently develop humoral hypercalcemia of malignancy (HHM) resulting from increased osteoclastic bone resorption. Our goal was to investigate the mechanisms of ATLL-induced osteoclastic bone resorption. Murine calvaria co-cultured with HTLV-1-infected cells directly or conditioned media from cell cultures had increased osteoclast activity that was dependent on RANKL, indicating that factors secreted from ATLL cells had a stimulatory effect on bone resorption. Factors released from resorbing bone stimulated proliferation of HTLV-1-infected T-cells. Parathyroid hormone-related protein (PTHrP) and macrophage inflammatory protein-1alpha (MIP-1alpha), both osteoclast stimulators, were expressed in HTLV-1-infected T-cell lines. Interestingly, when HTLV-1-infected T-cells were co-cultured with pre-osteoblasts, the expression of osteoprotegerin (OPG), an osteoclast inhibitory factor, was significantly down-regulated in the pre-osteoblasts. When OPG was added into the ex vivo osteoclastogenesis assay induced by HTLV-1-infected T-cells, osteoclastogenesis was strongly inhibited. In addition, HTLV-1-infected T-cells inhibited expression of early osteoblast genes and induced late genes. These regulators will serve as future therapeutic targets for the treatments of HHM in ATLL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.